Dr. Andrew Ko is currently a Professor of Clinical Medicine at the University of California San Francisco (UCSF), where he has been a member of the Hematology/Oncology faculty since 2001, including serving as Division Chief from 2018-22. He did his medical training at the Johns Hopkins School of Medicine, Beth Israel Hospital/Harvard Medical School, and Stanford University. His primary clinical and research interests focus on gastrointestinal cancers, particularly the development and evaluation of novel therapies for patients with pancreatic and upper-GI malignancies. He serves as chair of the NCI’s Pancreatic Cancer Task Force and has been an Associate Editor for gastrointestinal cancers for the Journal of Clinical Oncology since 2016. Additionally he has served on the scientific program committee, grants committee, and specialty editorial board for the American Society of Clinical Oncology; he plays an active leadership role in the Alliance for Clinical Trials in Oncology national cooperative group and sits on the National Comprehensive Cancer Network Pancreatic Cancer guidelines committee.
Last update: June 2022